Evidence mapPaperPMID 42447228Full record

ArticleRevista medica del Instituto Mexicano del Seguro Social2026

[Comment on the article: "Changes in the triglyceride-glucose index after one year of antiretroviral therapy"].

Gonzalo Enrique Flores-Guamán

Abstract readEnglish AbstractLetter
In one paragraph

Article in Revista medica del Instituto Mexicano del Seguro Social, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Gonzalo Enrique Flores-GuamánMédico General. Cuenca, Ecuador.ORCID 0009-0009-0827-0340

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Both HIV diagnosis and antiretroviral therapy (55.1%) increase the risk of developing lipid profile abnormalities. This has led the European Society of Cardiology, in its 2025 update on the management of dyslipidemias, to incorporate statin therapy in patients older than 40 years with an HIV diagnosis as primary prevention for atherosclerotic cardiovascular disease. These updates not only recommend strict control of the lipid profile in this population group, but also pharmacological therapy for the prevention of future cardiovascular events.

Indexed as

Anti-HIV AgentsBlood GlucoseDyslipidemiasHIV InfectionsTriglyceridesHumansAnti-HIV AgentsBlood GlucoseTriglyceridesCommunicable DiseasesDislipidemiasDyslipidemiasEnfermedades TransmisiblesHIVMetabolismMetabolismoVIH

Identifiers

PMID42447228
PMCPMC13378688

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.